$37.65
+7.9%Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Chief Development Officer
Chief Executive Officer, President, Treasurer & Director
Compensation
$891,283
Chief Financial Officer
Compensation
$675,536
Chief Information Officer & Head of Operations
Chief Operating Officer
Compensation
$281,110
Chief People Officer
Founder & Chief Scientific Officer
Founder & Independent Chairman
Compensation
$28,795
Head of Communications & Investor Relations
Senior Vice President of Medical Affairs
During the last 12 months, insiders have sold $37.94M worth of RAPP shares, with no buying activity reported.
0
0.00
912.4K
36.41M
-36.4M
-$36.41M
0
0.00
39.3K
1.12M
-1.1M
-$1.12M
0
0.00
15.2K
410.59K
-411K
-$411K
0
0.00
0
0.00
+0
+$0
No buying activity
Third Rock Ventures V, L.P.
10 Percent Owner
$34.39M
Yeleswaram Krishnaswamy
Officer: Chief Development Officer
$1.91M
Bredt David
Officer: Chief Scientific Officer
$842K
Gault Cheryl
Officer: Chief Operating Officer
$410K
Ceesay Abraham
Director, Officer: Chief Executive Officer
$395K
Strong bearish signal with $37.94M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
RAPP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 10, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 24, 2025 | June 17, 2025 | 2025 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.